NewcelX (f/k/a NLS Pharmaceutics) Completes Merger with Kadimastem Ltd.

NLS Pharmaceutics Merges with Kadimastem to Form NewCelX

June 27, 2025

Biotechnology

NLS Pharmaceutics Ltd. completed a $3.0 million equity financing to support its pending merger with Kadimastem Ltd.; the transaction closed and the combined company was re-named NewCelX Ltd. The deal brings together NLS's CNS-focused pipeline and Kadimastem's cell therapy programs (AstroRx and IsletRx) to advance clinical development for ALS, diabetes and other regenerative-medicine indications.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

Norstella and Citeline Merge to Create $5B Global Pharma Technology Company

June 28, 2022

Data & Analytics

Norstella (the group of Evaluate, MMIT, Panalgo and The Dedham Group) announced an agreement to merge with Citeline (formerly Pharma Intelligence) to form a combined global pharmaceutical technology and intelligence business valued at about $5 billion. The combination brings clinical trial intelligence, commercial data and real‑world analytics together to offer an end‑to‑end suite of solutions for life sciences companies; the deal involves financial sponsors including Hg (Norstella) and Warburg Pincus (Citeline).

Azelis Acquires Solchem Nature S.L. to Strengthen Nutraceutical Offering in Spain

April 7, 2025

Food & Beverage

Azelis has acquired 100% of Solchem Nature S.L., a Barcelona-based distributor of raw materials and premium ingredients for the nutraceutical and dietary supplements market. The deal expands Azelis's presence in Spain and adds Solchem's ~14-person team and network of over 250 customers to Azelis's EMEA nutraceutical platform.

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)

January 20, 2021

Biotechnology

Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.

Nordic Capital and Astorg Acquire Cytel from New Mountain Capital

December 21, 2020

Healthcare Services

Nordic Capital and Astorg have agreed to jointly acquire Cytel Inc. from New Mountain Capital. Cytel, a Waltham, Massachusetts–based provider of clinical trial design software, biometrics services and advanced analytics with more than 1,500 employees, will continue to be led by CEO Josh Schultz while the new owners invest to accelerate product development and growth; terms were not disclosed.